LOS ANGELES, March 23, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq: CAPR ), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that Linda Marbán, Ph.D., Chief Executive Officer, will present at the 3 rd Annual Alliance for Regenerative Medicine (ARM) Investor Day to be held Wednesday, March 25, 2015 in New York City.
The following are specific details regarding Capricor Therapeutics, Inc.'s presentation:
| Event: | ARM's Regen Med Investor Day |
| Date: | March 25, 2015 |
| Time: | 10:35 a.m. EDT |
| Location: | Metropolitan Club, One East 60th Street, New York, NY 10022 |
A live-streaming webcast of all panels and company presentations at the Annual Regen Med Investor Day will be available at: http://www.arminvestorday.com/webcast and will be published on the ARM event website shortly after the conference.
Editor's Note: Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org .
About Capricor Therapeutics
Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information, visit www.capricor.com .
Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 Investors: Robert Flamm, Ph.D. Russo Partners, LLC +1-212-845-4226 Media: Christopher Hippolyte Russo Partners, LLC +1-646-942-5634